• On Point - Episode 3

  • 2021/12/15
  • 再生時間： 11 分
  • ポッドキャスト

On Point - Episode 3

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • How does the syndromic approach impact confidence in treatment plans, as well as parent/patient satisfaction? Join Dr. Jennifer Baird as she discusses this topic with pediatrician Dr. Daniel Bruckner.

    This podcast was sponsored by BioFire Diagnostics

    More about the power of PCR diagnostic testing in point-of-care clinics here.

    This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

    BFR0001-3644-01 POC Podcast Episode 3
    続きを読む 一部表示

あらすじ・解説

How does the syndromic approach impact confidence in treatment plans, as well as parent/patient satisfaction? Join Dr. Jennifer Baird as she discusses this topic with pediatrician Dr. Daniel Bruckner.

This podcast was sponsored by BioFire Diagnostics

More about the power of PCR diagnostic testing in point-of-care clinics here.

This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; this product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

BFR0001-3644-01 POC Podcast Episode 3
続きを読む 一部表示

On Point - Episode 3に寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。